Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Ovarian Epithelial 2Unspecified Childhood Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Blast Crisis 1Astrocytoma 1

Interventions

aldesleukin 24Cyclophosphamide 14Interferon-alpha 10fludarabine 8fludarabine phosphate 7Interleukin-2 6Chemotherapy, Adjuvant 6sargramostim 5Neoadjuvant Therapy 5Fluorouracil 4Vincristine 3Sunitinib 3Magnetic Resonance Spectroscopy 3Dactinomycin 3Carboplatin 3Bevacizumab 3Amplified Fragment Length Polymorphism Analysis 3vandetanib 2valspodar 2tanespimycin 2ixabepilone 2carboxyamido-triazole 2bryostatin 1 2Vinblastine 2Thalidomide 2Temozolomide 2Sorafenib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Muromonab-CD3 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Kidney Neoplasms × irofulven × Clear all
NCT00003390 2013-06-21

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡